Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05622227 | 68Ga PET/CT Imaging in Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT05620004 | Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05620654 | A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin | unknown | Phase 1 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03792958 | Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 19 | AnewPharmaINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT04996771 | Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05559008 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | unknown | Phase 1 / Phase 2 | 116 | Ruijin HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05608785 | Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes | unknown | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 0 | Nov 8, 2022 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT03491631 | Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors | unknown | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2022 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT03540017 | HIPEC After Initial CRS in Patients Who Have Received NACT | unknown | Phase 1 | 15 | Northwell HealthOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603039 | A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 80 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02098512 | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | unknown | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596266 | CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Xuanwu Hospital, BeijingOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05135858 | Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma(METHOGLU) | unknown | Phase 1 | 18 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03750071 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | unknown | Phase 1 / Phase 2 | 30 | Vaximm GmbHINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05588206 | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 21 | First People's Hospital of HangzhouOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05027204 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | unknown | Phase 1 / Phase 2 | 94 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05577611 | An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | unknown | Phase 1 | 57 | Zhongnan HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04118868 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. | unknown | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04708210 | Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors | unknown | Phase 1 | 256 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05095441 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | unknown | Phase 1 | 51 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05569057 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | unknown | Phase 1 | 100 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 7, 2022 | clinicaltrials |
| NCT01946373 | T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma | unknown | Phase 1 | 20 | Karolinska University HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04765462 | Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT03864211 | Thermal Ablation Followed by Immunotherapy for HCC | unknown | Phase 1 / Phase 2 | 145 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05557903 | Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL | unknown | Phase 1 | 71 | Lanzhou Institute of Biological Products Co., LtdINDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT01197625 | Vaccine Therapy in Curative Resected Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04684472 | Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies | unknown | Phase 1 | 18 | Liqun ZouOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05552807 | SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 | 120 | Sinocelltech Ltd.INDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05549973 | Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 32 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT04688853 | A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients | unknown | Phase 1 | 26 | Gadeta B.V.INDUSTRY | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05528887 | Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies | unknown | Phase 1 | 10 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Sep 6, 2022 | clinicaltrials |
| NCT03478358 | Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors | unknown | Phase 1 | 60 | Peking Union Medical College HospitalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05518526 | Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases(ANNA-SARC) | unknown | Phase 1 / Phase 2 | 64 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT04262427 | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma(CAPER) | unknown | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05508620 | A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 270 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05416775 | Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 168 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05498636 | SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression | unknown | Phase 1 / Phase 2 | 67 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05507593 | Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 18, 2022source: clinicaltrials